157 
1 Recombinant DNA technology can contribute in 
2 a major way to our understanding of basic biological 
3 phenomena, and this knowledge in turn is bound to provide 
4 practical ways of dealing with very real medical problems, 
5 the very real medical problems of mankind. 
6 I believe that the implementation of these new 
7 revised guidelines is in the best interest of the public, 
8 and that they should be approved at the earliest possible 
g time. I personally endorse them wholeheartedly. 
10 MR. LIBASSI: Thank you very much. 
H Myron Levine? 
12 DR. LEVINE: Thank you. 
13 Ladies and gentlemen, I an speaking as an 
1 4 individual who has been involved in clinical research, 
15 including clinical research involving recombinant 
10 organisms. My current position is as Director of the 
17 Center for Vaccine Development at the University of 
10 Maryland School of Medicine, where I hold an appointment 
19 as Associate Professor of Infectious Diseases. 
20 Two points I would like to make ladies and 
21 gentlemen. One is that I feel the risks of preparing a 
22 pathogen advertently or inadvertently by recombinant 
23 DNA methods is miniscule, and I would like to point out 
24 some reasons why I believe this is so. Secondly, I would 
2s like to urge that priorities be reset with respect to 
[249] 
